Inquiry Basket
Loading ......
Filter By Product Search for
CCL17
CCL17 Full Name
chemokine (C-C motif) ligand 17
CCL17 Introduction
CCL17, also known as thymus and activation-regulated chemokine (TARC), is a member of the CC chemokine family that plays a pivotal role in directing immune cell migration and shaping inflammatory responses. Originally identified as a constitutively expressed chemokine in the thymus, CCL17 is now known to be produced by a variety of immune and non-immune cells, including dendritic cells, macrophages, endothelial cells, epithelial cells, and activated platelets. Through its interaction primarily with the chemokine receptor CCR4, and to a lesser extent CCR8, CCL17 orchestrates the recruitment of T helper 2 (Th2) lymphocytes, regulatory T cells, eosinophils, and other immune populations to sites of tissue inflammation. For researchers investigating immune-mediated diseases, understanding the CCL17–CCR4 signaling axis has become increasingly important because this pathway sits at the intersection of immune cell trafficking, cytokine regulation, and tissue-specific inflammatory responses. Recent studies have further expanded its biological significance beyond classical T-cell chemotaxis, revealing roles in neuroimmune communication, pain signaling, and tissue remodeling.
The growing interest in CCL17 stems from its strong association with chronic inflammatory and autoimmune disorders, where dysregulated immune cell recruitment drives disease progression. Elevated CCL17 expression has been reported in conditions such as atopic dermatitis, allergic asthma, rheumatoid arthritis, inflammatory bowel disease, and systemic autoimmune diseases. In these settings, excessive CCL17 production promotes the accumulation of CCR4-positive Th2 cells and contributes to persistent inflammation, fibrosis, and tissue damage. Emerging evidence also suggests that CCL17 participates in granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent inflammatory pathways that influence chronic pain development independently of traditional lymphocyte-mediated mechanisms. In the nervous system, increased CCL17 levels have been observed following both central and peripheral nerve injury, where it contributes to neuroinflammation and pain hypersensitivity. These findings have transformed the perception of CCL17 from a simple chemotactic factor into a multifunctional immune regulator with broad implications for inflammatory disease biology and therapeutic intervention.
Beyond inflammation, CCL17 has attracted considerable attention in oncology and cardiovascular research due to its involvement in disease-specific immune microenvironments. In classical Hodgkin lymphoma, malignant Hodgkin and Reed–Sternberg cells secrete large amounts of CCL17, creating a positive feedback loop that recruits Th2 cells and supports tumor survival, immune evasion, and disease progression. Circulating TARC/CCL17 levels have consequently emerged as one of the most valuable biomarkers for diagnosis, disease monitoring, treatment response assessment, and prognosis evaluation in this malignancy. More recently, vascular biology studies have identified CCL17 as a critical regulator of atherosclerosis, myocardial infarction, ischemic stroke, and other vascular inflammatory disorders by modulating regulatory T-cell homeostasis and immune balance within damaged tissues. As a result, the CCL17–CCR4 signaling pathway is increasingly being explored as a therapeutic target, with approaches including CCR4-blocking antibodies, receptor antagonists, and engineered cellular therapies. Although challenges remain regarding tissue-specific functions and potential off-target effects, accumulating evidence supports CCL17 as both a clinically relevant biomarker and a promising target for next-generation immunomodulatory therapies across autoimmune, inflammatory, cardiovascular, neurological, and oncological diseases.
Alternate Names for CCL17
CCL17; chemokine (C-C motif) ligand 17; TARC; ABCD-2; SCYA17; A-152E5.3; C-C motif chemokine 17; CC chemokine TARC; T cell-directed CC chemokine; small-inducible cytokine A17; thymus and activation-regulated chemokine; small inducible cytokine subfamily A (Cys-Cys), member 17;
Loading ......
